First Trust NYSE Arca Biotechnology Index Fund(FBT)

272.02+3.06+1.14%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Circio bolsters board as it advances circular RNA gene therapy platform
  TIPRANKS · 01:07
  Circio bolsters board as it advances circular RNA gene therapy platform
- Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study
  Reuters · 08-25 06:30
  Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study
- The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1
  THOMSON REUTERS · 08-25 06:30
  The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1
- Veracyte (VCYT) Receives a Buy from Piper Sandler
  TIPRANKS · 08-24 21:15
  Veracyte (VCYT) Receives a Buy from Piper Sandler
- Is Bruker’s (BRKR) AI Bet With Atinary Quietly Redefining Its Long-Term R&D Strategy?
  Simply Wall St. · 08-24 20:21
  Is Bruker’s (BRKR) AI Bet With Atinary Quietly Redefining Its Long-Term R&D Strategy?
- Regenxbio reports FDA placed clinical hold on RGX-121
  TIPRANKS · 08-24 19:20
  Regenxbio reports FDA placed clinical hold on RGX-121
- Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT)
  TIPRANKS · 08-21
  Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT)
- Corcept Therapeutics Director David L. Mahoney Sells 103,606 Shares Worth $12.26 Million
  Reuters · 08-21
  Corcept Therapeutics Director David L. Mahoney Sells 103,606 Shares Worth $12.26 Million
- Patent Cliffs Drive Pharma Expansion as Biotech M&A and IPO Markets Stage a Comeback
  Stock News · 08-19
  Patent Cliffs Drive Pharma Expansion as Biotech M&A and IPO Markets Stage a Comeback
- Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million
  Reuters · 08-19
  Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million
- BMO starts Exelixis at Market Perform into patent cliff
  TIPRANKS · 08-19
  BMO starts Exelixis at Market Perform into patent cliff
- Bruker Nano EVP, President Mark Munch Disposes of 4,984 Bruker Shares for $288,636.8
  Reuters · 08-19
  Bruker Nano EVP, President Mark Munch Disposes of 4,984 Bruker Shares for $288,636.8
- Genprex selects manufacturing organization for diabetes gene therapy
  TIPRANKS · 08-18
  Genprex selects manufacturing organization for diabetes gene therapy
- Corcept Therapeutics Incorporated : Truist Securities Assumes Coverage with Buy Rating; Target Price $164 vs $50
  THOMSON REUTERS · 08-18
  Corcept Therapeutics Incorporated : Truist Securities Assumes Coverage with Buy Rating; Target Price $164 vs $50
- Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99
  Reuters · 08-18
  Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99
- CANbridge Wins Taiwan NHIA Reimbursement for Rare Disease Drug Livmarli
  TIPRANKS · 08-18
  CANbridge Wins Taiwan NHIA Reimbursement for Rare Disease Drug Livmarli
- NEO Battery Raises $4 Million to Expand South Korean Battery Manufacturing
  TIPRANKS · 08-15
  NEO Battery Raises $4 Million to Expand South Korean Battery Manufacturing
- Bruker Board Declares Quarterly Cash Dividend for Shareholders
  TIPRANKS · 08-15
  Bruker Board Declares Quarterly Cash Dividend for Shareholders
- Bruker Declares Quarterly Cash Dividend of $0.05 a Share
  Reuters · 08-15
  Bruker Declares Quarterly Cash Dividend of $0.05 a Share
- Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
  Dow Jones · 08-14
  Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Company Profile
Company Name
First Trust NYSE Arca Biotechnology Index Fund
Market
ARCA
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.ftportfolios.com/Retail/etf/etfsummary.aspx?Ticker=FBT
Zip Code
- -
Phone
- -
Fax
- -
Introduction
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.

1D
5D
Day
Week
Month

Loading ...

High

272.91

Open

270.61

Volume%

0.83

Low

270.40

268.96

T/O Rate

0.48%

To The Moon

First Trust NYSE Arca Biotechnology Index Fund(FBT)

Company Profile

Most Discussed